Biological Control of Grapevine Crown Gall Disease, Caused by<i>Allorhizobium vitis</i>, Using<i>Paraburkholderia phytofirmans</i>PsJN

Biological Control of the Crown Gall Disease

A combination of the crown gall biocontrol strain K-84 and another antagonist JH-l was better than K-84 alone in controlling some Agrobacterium strains. Strain K-84 surprisingly controlled some resistant Agrobacterium strains when heavy concentrations of K-84 were used. Strain K-84 could control sensitive strains of Agrobacterium up to 48 hr. after wounds were inoculated with the pathogen at te...

Biological Control of the Crown Gall Diseases

Six different strains of crown gall bacteria were tested to determine whether the commonly used biocontrol strain, K-84, would present them from infecting the paradox hybrid. Previous research showed that K-84 was highly effective in preventing crown gall infections of English root stock. There was considerable variability among the six strains in ability to cause disease. One of the strains di...

Erratum to “Biological control for grapevine crown gall using nonpathogenic Rhizobium vitis strain ARK-1”

Biological control for grapevine crown gall using nonpathogenic Rhizobium vitis strain ARK-1

Crown gall of grapevine, which is caused by tumorigenic Rhizobium vitis, is the most important bacterial disease of grapevine throughout the world. Screening tests of biological control agents resulted in the discovery of a nonpathogenic R. vitis strain ARK-1. By soaking grapevine roots with a cell suspension of strain ARK-1 prior to planting in the field, ARK-1 treatment significantly reduced ...

Biological Control of Crown Gall on Grapevine and Root Colonization by Nonpathogenic Rhizobium vitis Strain ARK-1

A nonpathogenic strain of Rhizobium vitis ARK-1 was tested as a biological control agent for grapevine crown gall. When grapevine roots were soaked in a cell suspension of strain ARK-1 before planting in the field, the number of plants with tumors was reduced. The results from seven field trials from 2009 to 2012 were combined in a meta-analysis. The integrated relative risk after treatment wit...